---
document_datetime: 2025-07-18 16:37:56
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/talzenna-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: talzenna-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.7414265
conversion_datetime: 2025-12-25 12:32:25.358431
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Talzenna

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                       |
|----------------------|------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------------------|
| Variation type II /  | C.I HUMAN AND VETERINARY MEDICINAL | 05/06/2025                          |                                             | SmPC, Annex                      | SmPC new text Metastatic castration-resistant |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000248384   | PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of section 5.1 of the SmPC in order to include the final overall survival results from study C3441021 (TALAPRO-2) listed as a PAES in the Annex II.D, in order to fulfil ANX/01307; study C3441021 (TALAPRO-2) is a phase III, randomized, double blind, placebo controlled study of talazoparib with enzalutamide in metastatic castration resistant prostate cancer. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet and to bring the PI in line with the latest QRD template version 10.4.   | II and PL   | prostate cancer (mCRPC) TALAPRO-2 study […] A statistically significant improvement in BICR- assessed rPFS and OS was demonstrated for Talzenna in combination with enzalutamide compared to placebo in combination with enzalutamide. A sensitivity analysis of investigator- assessed rPFS was consistent with the BICR- assessed rPFS results. […] At the time of the final OS analysis, median rPFS was 33.1 months (95% CI: 27.4, 39.0) for patients who received Talzenna in combination with enzalutamide and 19.5 months (95% CI: 16.6, 24.7) for patients who received placebo in combination with enzalutamide (hazard ratio=0.667, 95% CI: 0.551, 0.807). Efficacy results of TALAPRO-2 are provided in Tables 7 and 8, and Figures 4, 5, 6 and 7. […] At the time of the final OS analysis, in the HRRm subgroup median rPFS was 27.7 months (95% CI: 19.3, 38.4) for patients who received Talzenna in combination with enzalutamide and 13.8 months (95% CI: 10.8, 19.3) for patients who received placebo in combination with enzalutamide (hazard ratio=0.454, 95% CI: 0.305, 0.674); in the non- HRRm subgroup median rPFS was 33.2 months (95% CI: 25.9, 44.2) for patients who received Talzenna in combination with enzalutamide and 22.1 months (95% CI: 16.6, 30.4) for patients who received placebo in combination with enzalutamide (hazard ratio=0.740, 95% CI: 0.565, 0.969); in the BRCAm subgroup median rPFS was not reached (95% CI: 16.8, Not Reached) for patients who received Talzenna in combination with enzalutamide   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| and 11 months (95% CI: 5.9, 13.8) for patients who received placebo in combination with enzalutamide (hazard ratio=0.259, 95% CI: 0.120, 0.558).   |
|----------------------------------------------------------------------------------------------------------------------------------------------------|